Star Scientific Reports Publication of First Peer-Reviewed Article on the Effects of Anatabine in an Animal Model of Multiple

  Star Scientific Reports Publication of First Peer-Reviewed Article on the
        Effects of Anatabine in an Animal Model of Multiple Sclerosis

PR Newswire

GLEN ALLEN, Va., Jan. 31, 2013

GLEN ALLEN, Va., Jan. 31, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ:
STSI) today announces publication of the first peer-reviewed article examining
the effects of anatabine in a mouse model of the debilitating autoimmune and
neurodegenerative disease multiple sclerosis (MS). The study, conducted by
the Company's research partner, The Roskamp Institute, was designed to
determine whether anatabine had beneficial effects on the development of
experimental autoimmune encephalomyelitis (EAE) in mice, which is a standard
mouse model of MS. Some of the findings were previously presented at
Neuroscience 2012, an international scientific convention; however, the
article in PLOS ONE contains complete results of the study, and the
articlewas subjected to the peer review evaluation process prior to
publication.

(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO )

The Roskamp researchers found that orally administered anatabine significantly
reduced neurological disability and improved motor coordination of EAE mice.
In particular, paralysis of the hind limbs was markedly suppressed in the
anatabine treated group, and neurological symptoms were delayed in the
anatabine treated group compared to the placebo group.

The study results also showed that anatabine supplementation resulted in
suppression of several pro-inflammatory molecules (cytokines) in the blood and
in the spleen of the EAE mice. The observed reduction in the levels of
several inflammatory molecules provides evidence that the experimental
autoimmune process has been reduced. Anatabine also significantly suppressed
STAT3 and NF-kB activation in the spleen and the brain of the EAE mice. These
two intracellular transcription factors (proteins) regulate a large array of
inflammatory genes including cytokines, suggesting a mechanism by which
anatabine antagonizes pro-inflammatory cytokine production.

In addition, the researchers found that anatabine reduced the infiltration of
inflammatory cells in the brain and significantly prevented demyelination in
the spinal cord of EAE mice. In humans, demyelination in the spinal cord is
associated with muscle weakness and paralysis in MS. Therefore, the
researchers concluded that the "data suggest that anatabine may be effective
in the treatment of MS."

Dr. Michael Mullan, President and CEO of the Roskamp Institute, commented,
"The most remarkable results were the clear inhibition of brain inflammation
and thedegeneration of the spinal cord by anatabine and the accompanying
inhibition of the severe paralysis that usually accompanied the model."

Dr. Daniel Paris, the primary author of the article and Head of Research and
Development at the Roskamp Institute, added, "The oral administration of
anatabine potently reduced the neurological deficits and abrogated the
pathological lesions in the spinal cord that are responsible for the
development of paralysis in this mouse model of multiple sclerosis (MS). In
addition our work also explains the beneficial activity of anatabine in this
MS model by showing that this compound prevents the activation of key
molecules that orchestrate the propagation of inflammation in the central
nervous system and the periphery."

The full title of the study is, "Amelioration of Experimental Autoimmune
Encephalomyelitis by Anatabine," and can be viewed here:
http://dx.plos.org/10.1371/journal.pone.0055392. This study builds upon
earlier research conducted by the Roskamp Institute, which showed that the
natural alkaloid anatabine displays anti-inflammatory properties and readily
crosses the blood brain barrier, suggesting it could represent an important
compound for mitigating many types of neuro-inflammatory conditions.

PLOS ONE is an international, peer-reviewed, open-access, scientific journal.

Certain statements contained in this release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to statements identified
by words such as "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The statements in this
release are based upon the current beliefs and expectations of our company's
management and are subject to significant risks and uncertainties. Actual
results may differ from those set forth in the forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but
not limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives, including the
continued development and market acceptance of our nutraceutical products, the
effect of any competitive products, our ability to license and protect our
intellectual property, our ability to raise additional capital in the future
that is necessary to maintain our business, changes in government policy
and/or regulation, as well as other risks discussed from time to time in our
filings with the Securities and Exchange Commission, including, without
limitation, our annual report on Form 10-K for the fiscal year ended December
31, 2011. We undertake no duty to update any forward-looking statement or any
information contained in this press release or in other public disclosures at
any time.

About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to
promote maintenance of a healthy metabolism and lifestyle. Over the last
several years, through its wholly owned subsidiary, Rock Creek
Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale,
and marketing of two nutraceutical dietary supplements, and the development of
other nutraceuticals and pharmaceuticals. The company also continues to pursue
the licensing of the technology behind its proprietary StarCuredĀ® curing
process and its related products. Rock Creek Pharmaceuticals has scientific
and research offices in Gloucester, MA, and a regulatory office in Washington,
DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, and an
Executive, Scientific & Regulatory Affairs office in Washington, DC.

Contact:
Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.
(202)887-5100
ttuck@starscientific.com

SOURCE Star Scientific, Inc.

Website: http://www.starscientific.com
 
Press spacebar to pause and continue. Press esc to stop.